ALNYLAM PHARMACEUTICALS, INC. (ALNY) Return on equity 2016–2025
ALNYLAM PHARMACEUTICALS, INC. (ALNY) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
39.8%FY2025 · since FY2016: -44.6% → 39.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 39.8% | +454.4 pp |
| FY2024 | -414.6% | — |
| FY2021 | -145.0% | -60.5 pp |
| FY2020 | -84.5% | -22.9 pp |
| FY2019 | -61.6% | -3.1 pp |
| FY2018 | -58.5% | -30.7 pp |
| FY2017 | -27.8% | +16.8 pp |
| FY2016 | -44.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ALNY financial trends
ALNY RevenueALNY Net incomeALNY Net marginALNY Gross profitALNY Gross marginALNY Operating incomeALNY Operating marginALNY Operating cash flowALNY Free cash flowALNY Capital expendituresALNY Stock buybacksALNY Dividends paidALNY Total assetsALNY Total liabilitiesALNY Shareholders’ equityALNY overview →